Active — Not RecruitingNot Applicable

A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

China154 participantsStarted 2024-01-17

Plain-language summary

The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years.
✓. Participant with histologically/cytologically confirmed locally advanced or metastatic NSCLC.
✓. Participants with ALK gene rearrangement confirmed by local hospital medical records.
✓. Participants who received brigatinib since September 1, 2022 as first line treatment confirmed by medical records.
✓. Participants who have at least one medical record after the start of brigatinib treatment.

Exclusion criteria

✕. Participants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment.
✕. Previously received any other TKIs, including ALK-targeted TKIs.
✕. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.
✕. Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.

What they're measuring

Real-World Time-to-Treatment Discontinuation (rwTDD)

Timeframe: Up to 8 years

Trial details

NCT IDNCT05721950

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-03-20

View on ClinicalTrials.gov More Non-small Cell Lung Cancer (NSCLC) trials